Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports

TL;DR

Telitacicept improves symptoms in three patients with coexisting myasthenia gravis and connective tissue disease, offering a promising new treatment approach.

Contribution

Demonstrates telitacicept as a double-target therapy for rare co-occurring autoimmune conditions.

Findings

Three patients showed significant improvement within 4-7 weeks of telitacicept treatment.

Telitacicept allowed reduced prednisone use while maintaining control of connective tissue disease symptoms.

Abstract

Myasthenia gravis (MG) and connective tissue diseases (CTD) are both B-cell-mediated, antibody-associated autoimmune diseases that share similar mechanisms of immune dysfunction. The coexistence of MG and CTD is a rare phenomenon, and its management remains challenging. Here, we report three cases of coexisting MG and CTD—specifically systemic lupus erythematosus and Sjögren’s syndrome, and all three patients presented significant improvement 4 weeks after initiation of treatment with telitacicept. Minimal symptom expression (MSE) was achieved after 4, 6, and 7 weeks of treatment with telitacicept, for patients one-to-three, respectively. This therapy also enabled a reduction in prednisone dosage, with clinical symptoms of CTD remaining well controlled. These findings present preliminary evidence supporting Telitacicept as an effective treatment and a double-target therapy for the management of MG-CTD.

Figures